Platinum(IV)-chlorotoxin (CTX) conjugates for targeting cancer cells
Name
Lippard_Platinum(IV)-chlorotoxin.pdf
Size
625.08 KB
Format
Adobe PDF
Checksum (MD5)
e821d20b6ee59ed331dfe6f9dbe3899f
Author(s)
Graf, Nora
Mokhtari, Tara E.
Papayannopoulos, Ioannis A.
Lippard, Stephen J.
Date Issued
February 2012
Journal
Journal of Inorganic Biochemistry
Publisher
Elsevier
Citation
Graf, Nora, Tara E. Mokhtari, Ioannis A. Papayannopoulos, and Stephen J. Lippard. “Platinum(IV)-Chlorotoxin (CTX) Conjugates for Targeting Cancer Cells.” Journal of Inorganic Biochemistry 110 (May 2012): 58–63.
Version
Author's final manuscript
Abstract
Cisplatin is one of the most widely used anticancer drugs. Its side effects, however, have motivated researchers to search for equally effective analogs that are better tolerated. Selectively targeting cancer tissue is one promising strategy. For this purpose, a platinum(IV) complex was conjugated to the cancer-targeting peptide chlorotoxin (CTX, TM601) in order to deliver cisplatin selectively to cancer cells. The 1:1 Pt-CTX conjugate was characterized by mass spectrometry and gel electrophoresis. Like most platinum(IV) derivatives, the cytotoxicity of the conjugate was lower in cell culture than that of cisplatin, but greater than those of its Pt(IV) precursor and CTX in several cancer cell lines.
MIT Department
Massachusetts Institute of Technology. Department of Chemistry
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.jinorgbio.2012.02.012
